1Michael SB, Enrique FS. Selecting controls is not selecting"normals":design and analysis issues for studying the etiology of polycystic ovary syndrome [J]. Fertil Steril, 2006,86 (1) : 1-12.
3Hart R. Polycystic ovarian syndrome: prognosis and treatment outcomes[J]. Curr Opin Obstet Gynecol,2007,19(6) :529-535.
4Diamanti-Kandarakis E, Christakou C, Kandarakis H. Polycystic ovarian syndrome:the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome[J]. Minerva Endocrinol,2007,32(1) :35-47.
5Glueck C J, Papanna R, Wang P, et al. Incidence and tratment of metabolic syndrome in newly referred women with confimed polycystic ovarian syndeome [J]. METABOLISM, 2003,52 (7): 908-915.
1Karacan E,Caglar GS, Giirsoy AY, et al. Body Satisfaction and Eating Attitudes among Girls and Young Women with and without Polycystic Ovary Syndrome[J]. J Pediatr Adolesc Gynecol, 2014,27 ( 2 ) :72 -77.
2Karakfise M, Cakal E, Ertan K, et al. The metabolic effects of drugs used for the treatment of polycystic ovary syndrome[ J]. J Turk Ger Gy- necol Assoc,2013,14 (3) : 168-173.
3Premoli AC, Santana LF, Ferriani RA, et al. Growth hma'none secretion and insulin like growth factor 1 are related to hyperandrogenism in non- obese patients with polycystic ovary syndrome [ J ]. Fertil Steril,2005, 83(6) :1852-1855.
4Ersan F, Arslan E, Esmer Aq, et al. Prediction of metabolic syndrome in women with polycystic ovary syndrome [ J ]. J Turk Ger Gynecol As- soc,2012,13(3) :178-183.
